<DOC>
	<DOCNO>NCT00199836</DOCNO>
	<brief_summary>This cancer vaccine research study involve injection NY-ESO-1b peptide along 2 agent help stimulate immune system . Peptides small fragment every protein . These peptide normally find testis placenta . They also find various type cancer cell . The purpose stimulate immune system react peptide find cancer cell</brief_summary>
	<brief_title>A Pilot Study NY-ESO-1b Peptide Plus CpG 7909 Montanide ISA-51 Patients With Cancer .</brief_title>
	<detailed_description>This pilot study patient HLA-A2 phenotype whose tumor express NY-ESO-1 LAGE-1 antigen . Patients receive NY-ESO-1b peptide mix 0.5mL Montanide ISA-51 1mg CpG7909 give every three week four dos subcutaneous injection . There three-week follow-up period fourth injection make cycle 13 week long . In absence toxicity progressive disease , second cycle offer patient receive four vaccination . The primary objective evaluate immune response ( antibody , CD8+ T cell , DTH ) safety vaccination NY-ESO-1b peptide mix CpG 7909 Montanide patient cancer express NY-ESO-1 LAGE-1 . The secondary objective document tumor responses patient evaluable measurable disease .</detailed_description>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Metastatic , measurable cancer resect high risk Stage III/IV ; resect Stage II , III , IV non small cell lung cancer esophageal cancer decline , fail , complete standard therapy ; tumor expression NYESO1 LAGE1 antigen ; HLAA2 positive ; karnofsky performance status great equal 60 % ; hematology biochemistry laboratory result within limit normally expect patient population . Clinically significant heart disease ; serious illness ; patient serious intercurrent illness , require hospitalization ; patient take immunosuppressive drug ; autoimmune disease ; know HIV positivity ; active malignancy within 1 year prior entry study ; participation chemotherapy , radiation therapy , clinical trial involve another investigational agent within 4 week prior enrollment ; pregnancy breastfeeding ; woman childbearing potential : Refusal inability use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>cancer vaccine</keyword>
	<keyword>NY-ESO-1b peptide</keyword>
	<keyword>CpG 7909</keyword>
	<keyword>Montanide ISA-51</keyword>
	<keyword>LAGE-1</keyword>
	<keyword>immune response</keyword>
	<keyword>safety</keyword>
</DOC>